Cardiovascular intervention company Medinol Ltd announced on Monday the successful First-in-Human implantation of its ChampioNIR Drug-Eluting Peripheral Stent by Drs Gerard S. Goh and Thodur Vasudevan at Alfred Hospital in Melbourne, Australia.

This stent introduces a groundbreaking advancement in peripheral drug-eluting stent technology, improving both mechanics and durability. ChampioNIR features a hybrid mechanical design with radial support from a metallic component and longitudinal flexibility provided by a bioresorbable polymeric mesh. This combination enhances flexibility and durability in complex anatomies. Its innovative drug-elution system delivers medication across the entire stent surface, allowing extended therapeutic dosing in large peripheral vessels.

The CHAMPIONSHIP study will enroll 30 patients across seven sites in Australia and the United States.